Sugi Predict

Sugi Predict / Compounds / SCHEMBL1999188

SCHEMBL1999188

SCHEMBL1999188

O=c1ccn([C@]2(C(F)(F)F)O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SLC28A1 O00337 1/20 0.48
▸ SLC28A2 O43868 1/20 0.48
▸ SLC29A1 Q99808 1/20 0.48
▸ SLC28A3 Q9HAS3 1/20 0.48
▸ P2RY14 Q15391 4/20 0.40
▸ P2RY2 P41231 6/20 0.36
▸ P2RY6 Q15077 6/20 0.35
▸ P2RY4 P51582 2/20 0.35
▸ PYGB P11216 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL21465157 0.95 SLC28A1 (0.44) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL30139074 0.89 SLC28A1 (0.40) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL4085513 0.86 SLC28A1 (0.43) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL3827540 0.85 SLC28A1 (0.42) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL98410 0.83 SLC28A1 (0.49) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL30514301 0.83 SLC28A1 (0.51) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Water SCHEMBL27625510 0.82 SLC28A1 (0.48) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Hydrochloric Acid SCHEMBL10584588 0.82 SLC28A1 (0.48) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL42133 0.82 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL6002015 0.82 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125630-A1 METHOD FOR BIOPROTAC DESIGN MEDIMMUNE LIMITED (GB) 2025-06-19 — — WO disclosed
WO-2024151673-A2 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-07-18 — — WO disclosed
WO-2024151685-A1 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-07-18 — — WO disclosed
EP-4387596-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GlaxoSmithKline Biologicals SA (BE) 2024-06-26 — — EP disclosed
WO-2024077191-A1 NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONALPOLYPEPTIDES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-04-11 — — WO disclosed
WO-2024064965-A2 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) 2024-03-28 — — WO disclosed
WO-2023242817-A2 RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-12-21 — — WO disclosed
EP-4277651-A1 <SMALLCAPS/>? ? ?STAPHYLOCOCCUS? ? ? ? ?AUREUS ANTIGEN-BASED NUCLEIC ACID VACCINES University of Rochester (US) 2023-11-22 — — EP disclosed
CN-115850356-A Deoxynucleoside analogue and preparation method thereof 华东理工大学 2023-03-28 — — CN disclosed
WO-2023021421-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 — — WO disclosed
EP-2338985-A1 Thermostable biocatalyst combination for nucleoside synthesis Institut Univ. de Ciència i Tecnologia, s.a. (ES) 2011-06-29 — — EP disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 — — US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 — — EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 — — WO disclosed
EP-0635517-B1 Process for Producing 1-(2'-deoxy-beta-D-erythropentofuranosyl)-5-trifluoromethyluracil Derivatives MITSUI CHEMICALS INC (JP) 2000-05-17 — — EP disclosed
EP-0990651-A1 Process for producing 5-trifluoromethyluracil derivatives Mitsui Chemicals, Inc. (JP) 2000-04-05 — — EP disclosed
US-5532349-A ANTITUMOR, VIRICIDES MITSUI TOATSU CHEMICALS, INC. (JP) 1996-07-02 — — US disclosed
EP-0635517-A1 Process for Producing 1-(2'-deoxy-beta-D-erythropentofuranosyl)-5-trifluoromethyluracil Derivatives MITSUI TOATSU CHEMICALS, Inc. (JP) 1995-01-25 — — EP disclosed
CN-1065462-A Replace 2 ', 3 '-dideoxy-5-trifluoromethyl uridine diphosphate glycoside, their preparation method and they application aspect medical BAYER AG (DE) 1992-10-21 — — CN disclosed
EP-0233493-A2 Process for producing ribonucleosides Yamasa Shoyu Kabushiki Kaisha (JP) 1987-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ SLC28A1 906/4885SLC28A2 815/4885SLC29A1 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.